Drexel University Home Pagewww.drexel.edu DREXEL UNIVERSITY LIBRARIES HOMEPAGE >>
iDEA DREXEL ARCHIVES >>

iDEA: Drexel E-repository and Archives > Drexel Theses and Dissertations > Drexel Theses and Dissertations > Development of novel PLGA contrast agents for use as ultrasound targeted drug delivery vehicles

Please use this identifier to cite or link to this item: http://hdl.handle.net/1860/182

Title: Development of novel PLGA contrast agents for use as ultrasound targeted drug delivery vehicles
Authors: El-Sherif, Dalia
Keywords: Ultrasonic imaging;Contrast media;Diagnostic imaging
Issue Date: 29-Jul-2003
Abstract: Ultrasound is limited in its ability to distinguish between diseased and normal tissue. This limitation has led to the development of contrast agents. We have produced novel air-filled microcapsules of poly (lactic-co-glycolic) acid (PLGA/PLA) that work well as ultrasound contrast agents. The agent demonstrated acoustic enhancements up to 24 dB in vitro and in vivo. Furthermore, in vivo Doppler enhancements of a rabbit kidney were reported with injections of a 0.1mL/kg dose. The rabbits did not show any side effects from multiple injections (24) of the agent. The contrast agent was fabricated by modifying a double emulsion method to encapsulate sublimable materials in the oil and aqueous phases. The encapsulated materials were then sublimed, leaving a void in their place. The degradation of contrast agents was found to be closely related to both capsule morphology and insonation frequency at which they were exposed. Agent degradation was monitored by high performance liquid chromatography (HPLC). Amounts of lactic and glycolic acids produced were quantified. Glycolic acid repeat units showed a greater degradation rate than lactic acid units. Additional in vitro studies were carried out to further optimize and characterize the agent. The surfactant solution temperature was found to play an important role in agent morphology and acoustic response. An attenuation study indicated that their resonance frequency was ~2 MHz. Furthermore, in vivo and in vitro studies concluded that the 50:50 PLGA agent is temperature sensitive, lasting up to 20 min at 255C (minimal loss of signal (4 dB), while at 37sC the signal drops close to baseline with in the first 5 minutes. It was concluded that fabrication of the contrast agent with a more hydrophobic polymer extends its acoustic time response. Preliminary drug delivery and targeting studies were also investigated. The reported results are promising and lay the foundation for future work. This research has led to the development of novel PLGA/PLA contrast agents that have shown potential use for targeted drug delivery vehicles.
URI: http://dspace.library.drexel.edu/handle/1860/182
Appears in Collections:Drexel Theses and Dissertations

Files in This Item:

File Description SizeFormat
el-sherif_thesis.pdf13.78 MBAdobe PDFView/Open
View Statistics

Items in iDEA are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! iDEA Software Copyright © 2002-2010  Duraspace - Feedback